Family Health, Nottingham Children s Hospital Date of submission February 2018
|
|
- Ophelia Brown
- 5 years ago
- Views:
Transcription
1 Nusinersen Title of Guideline Guideline for the prescribing and administration of Nusinersen to patients with Spinal Muscular Atrophy Type 1 Contact Name and Job Title (author) Dr Gabriel Chow- Consultant Paediatric Neurologist Dr Simone Stokley- Consultant Paediatric Haematologist/ Trust Intrathecal Lead Andrew Wignell - Senior Paediatric Pharmacist Directorate & Speciality Family Health, Nottingham Children s Hospital Date of submission February 2018 Date on which guideline must be reviewed (this should be one to three years) Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Abstract Key Words Statement of the evidence base of the guideline has the guideline been peer reviewed by colleagues? Evidence base: (1-5) 1a meta analysis of randomised controlled trials 1b at least one randomised controlled trial 2a at least one well-designed controlled study without randomisation 2b at least one other type of well-designed quasiexperimental study 3 well designed non-experimental descriptive studies (i.e. comparative / correlation and case studies) 4 expert committee reports or opinions and / or clinical experiences of respected authorities 5 recommended best practise based on the clinical experience of the guideline developer February 2020 Children with Spinal Muscular Atrophy Type 1 This guideline is intended to provide clear guidance on the use of nusinersen in the management of Children with Spinal Muscular Atrophy Type 1 Treatment can only be initiated by a Consultant Paediatric Neurologist. Paediatric, Children, Spinal Muscular Atrophy, Nusinersen 1b. Use is in line with the NHS England (2017) Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP). Consultation Process Paediatric Neurology, Paediatric Haematology, Paediatric Oncology, Pharmacy, NUH Drugs and Therapeutics Committee. Target audience Medical, nursing and pharmacy staff working at Nottingham Children s Hospital This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date. Lead Author: Gabriel Chow Page 1 of 8 September 2017
2 Document Control Document Amendment Record Version Issue Date Author V1 Feb 2018 Dr G Chow, Consultant Paediatric Neurologist Dr S Stockley, Consultant Paediatric Haematologist Andrew Wignell, Senior Paediatric Pharmacist Statement of Compliance with Child Health Guidelines SOP This guideline refers to activities of only one specific team and consultation has taken place with relevant members of that team. Therefore this version has not been circulated for wider review. Maria Moran Clinical Guideline Lead 27 th February 2018 Lead Author: Gabriel Chow Page 2 of 8 September 2017
3 Background Spinal Muscular Atrophy Type 1 (SMA1) is the most common fatal genetic disease of infancy; children die in childhood of muscle weakness. Until now there has been no treatment. Nusinersen is an investigational disease-modifying drug, which works by increasing the amount of functional SMN protein, by altering the splicing of pre-mrna from the SMN2 gene. Biogen, the manufacturer of Nusinersen, reported that the drug met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with Type 1) SMA. The analysis 1 found that infants receiving nusinersen experienced a statistically significant improvement in the achievement of motor milestones compared to those who did not receive treatment. Nusinersen demonstrated an acceptable safety profile in the trial. Nusinersen is now licenced in the UK for the treatment of SMA1. The manufacturer s Summary of Product Characteristics ( data sheet ) can be found here: Commissioning of Nusinersen Treatment Based on a limited scoping of the evidence, NHS England has concluded that there is sufficient evidence to support a proposal for the routine commissioning of this treatment for SMA Type 1 as outlined in the starting criteria below 2. The medicine will be provided free of charge by Biogen under an Early Access Programme (EAP); NHS England will reimburse Trusts for the activity associated with drug administration. Criteria for stopping treatment have also been stipulated by NHS England. Starting Criteria Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygote. SMN2 copy number = 2. Onset of clinical signs and symptoms consistent with SMA at 6 months (180 days) of age. Males and females 7 months (210 days) of age at Screening. Receiving adequate nutrition and hydration (with or without gastrostomy). Body weight 3rd percentile for age using appropriate country-specific guidelines. Medical care, such as routine immunisations (including influenza vaccine, pneumococcus vaccine, and respiratory syncytial virus prophylaxis (palivizumab) if available), meets and is expected to continue to meet guidelines set out in the Consensus Statement for Standard of Care in SMA. Exclusion criteria SMA1A (also called SMA0) is a special category by virtue of its extreme severity, Lead Author: Gabriel Chow Page 3 of 8 September 2017
4 and which requires discussion with the parents on the basis that SMA1A infants are very unlikely to respond to Nusinersen. Thus nusinersen EAP will not be an appropriate intervention for SMA 1A infants. Comorbidities that might preclude lumbar puncture. Hypoxaemia (O2 saturation awake <96% or O2 saturation asleep <96%, without ventilation support) during screening evaluation. Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy. History of brain or spinal cord disease that would interfere with the lumbar puncture procedures, cerebrospinal fluid (CSF) circulation, or safety assessments. Untreated bleeding disorders or any other existing condition which precludes lumbar punctures. Spinal fusion in most instances (needs further assessment with orthopaedic surgeons). Stopping Criteria For patients on 24 hour non-invasive ventilation (NIV), if there is no improvement in motor score, assessed by the Hammersmith Infant Neurological Examination (HINE), or NIV requirement improvement - then treatment should discontinue after the 5th dose of nusinersen treatment. For patients on less than 24 hour NIV, maintenance of respiratory function with NIV (i.e. need for the same number of hours NIV (for example a patient receiving 16 hours NIV per day continues to need 16 hours per day, or one on 22 hours per day continues to need 22 hours) may be viewed as stabilisation and an indication of benefit - so nusinersen treatment will continue. HINE score will also be calculated, and stability or improvement on the HINE score will be considered an indication to continue nusinersen administration. If in the parents view the quality of life is poor because of SMA1 disability progression, or adverse effects of nusinersen administration procedure or drug side effects, then there is a need to discuss nusinersen discontinuation. If the view of the treating physician is that the handling and positioning required for lumbar puncture or a general anaesthetic required for this procedure, impose significant life-threatening risk in a fragile SMA1 infant, this would be considered as an indication to stop nusinersen EAP participation. There may be additional unforeseen circumstances / worsening of clinical status, which may necessitate a discussion with the parents to discontinue nusinersen treatment. Contraindications Nusinersen will not be offered to patients with other life limiting conditions or if it is contraindicated to treatment as set out in the Summary of Product Characteristics. Lead Author: Gabriel Chow Page 4 of 8 September 2017
5 Adverse Effects Most common adverse reactions reported: fever, lower respiratory infection, upper respiratory infection and constipation Other reported adverse reactions: teething, upper respiratory tract congestion, aspiration, ear infection, scoliosis, rash, reduction in growth, respiratory distress, respiratory failure, salivary hypersecretion, atelectasis, nasopharyngitis, nausea and vomiting Reported side effects of intrathecal injections include: headache, back pain, infection, bleeding near the puncture site (rarely into the epidural space) and transient or persistent cerebrospinal fluid leakage (post lumbar puncture syndrome) Dosing The Nusinersen dose is 5ml = 12mg, given by the intrathecal route. This is not age dependent. Four loading doses are given in the first 2 months on days 1, 15, 30 and 60. A maintenance dose is then given every 4 months thereafter. If a loading dose is delayed or missed, administer nusinersen as soon as possible, with at least 14-days between doses and then continue dosing as prescribed. Consent and Planning Once a patient is identified by Dr Chow or another neurologist, they should inform the medical intrathecal lead for Queen s Medical Centre or one of the other paediatric haematologists/oncologists who will decide with Dr Chow when the child should start treatment. The Neurologist would determine whether the procedure was to be completed with or without general anaesthetic. Most children under the age of 2 years should manage well with local anaesthetic. Consent will be taken by the Neurologist for both the lumbar puncture and intrathecal administration of Nusinersen. Prescribing and Administration Nusinersen must be prescribed by a Consultant Paediatric Neurologist. The administrator of the drug will be a Paediatric oncologist/haematologist who is on the Trust Intrathecal Register. This will require annual training and assessment of competence. The medical intrathecal lead for Queen s Medical Centre will advise on the necessary training. Each dose needs to be prescribed separately, but up to a year s worth of doses may be written up at any one time. If a treatment dates change following the initial prescription, the prescription can be re-dated (with the prescriber making Lead Author: Gabriel Chow Page 5 of 8 September 2017
6 the change annotating the prescription with their initials, printed name and the date the change was made). The prescriptions should be written on a specific nusinersen intrathecal drug chart. Administration will take place at the end of an oncology intrathecal list on E39 Day Care. All staff involved in the administration of the drug must be on the Children s Hospital Intrathecal Register. A detailed protocol covering administration is included as Appendix 1 of this guideline. Preparation, Delivery and Storage of Medication The required dose will be drawn up in the Pharmacy Sterile Production Unit into a NRFit Spinal Syringe. After release from the production unit, the dose will be delivered to E39 Day Care following the normal intrathecal procedures. Delivery of Nusinersen to the ward must be separate to the delivery of intrathecal chemotherapy. All personnel involved in delivery and receipt of the prepared dose must be the Children s Hospital Intrathecal Register. Nusinersen must be stored separately to other medicines, including other intrathecals. It must be stored at room temperature in a designated locked cupboard separate to all other medicines. Lead Author: Gabriel Chow Page 6 of 8 September 2017
7 References 1) European Medicines Agency (2017) European Public Assessment Report: Spinraza. _Public_assessment_report/human/004312/WC pdf 2) NHS England (2017) Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP). Lead Author: Gabriel Chow Page 7 of 8 September 2017
8 Appendix 1: Protocol for Drug Administration Pre-Procedure Checklist Check Consent for Lumbar puncture and nusinersen intrathecal administration Check that LP needle is available Check that the nurse checking nusinersen, and Doctor due to administer it intrathecally, are on the intrathecal register. Check the patient is fit for procedure Check blood/urine results (clotting, FBC and urine protein)- before start of course of EAP treatment, or taken with last dose, whichever is most recent). This is the responsibility of the Paediatric Neurology Team. Check prescription and treatment protocol Check that oxygen saturations >95% before procedure Protocol for lumbar puncture and intrathecal administration: Wash hands wear sterile gloves before commencing the procedure in a non touch aseptic manner. Strict aseptic technique. Lumbar puncture must be performed with a non-luer NRFit syringe. NRFit intrathecal Kit is obtained from NHS Supply Chain. Once the lumbar puncture needle is in place, approximately 3 5 ml of CSF should be drained (collected and saved if indicated) through the lumbar puncture needle prior to dose administration. If a lumbar puncture (LP) is technically difficult and requires the assistance (doing the LP to obtain successful spinal CSF tap) of someone else whose name does not appear on the register, this is acceptable but these staff must never be involved in any other aspect of the process and must never administer the intrathecal nusinersen. The nusinersen syringe, which has a non-luer NRFit tip, should be directly attached to the hub of the lumbar puncture NRFit needle. The drug solution should be injected slowly, over the course of 1 minute. Once the procedure has been completed, the puncture site should be covered with an adhesive bandage or occlusive dressing. Doctor and IT registered nurse to sign the prescription to record drug administration. Lead Author: Gabriel Chow Page 8 of 8 September 2017
Spinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Spinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through
More informationClinical Policy Bulletin: Nusinersen (Spinraza)
Clinical Policy Bulletin: Nusinersen (Spinraza) Number: 0915 Policy *Pleasesee amendment forpennsylvaniamedicaidattheendofthiscpb. Note: REQUIRES PRECERTIFICATION.Footnotes for Precertification of nusinersen
More informationLetter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy
TEMPLATE Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Date: [Insert Name of Medical Director] RE: Patient Name [ ] [Insurance Company] Policy Number [ ] [Address]
More informationIdiopathic Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura Title of Guideline Contact Name and Job Title (author) Directorate & Speciality Guideline for the management of idiopathic thrombocytopenic purpura Dr S Stokley, Consultant
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 11.28.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More information1. Intrathecal must never be abbreviated to IT on a prescription form True / False
Appendix 1: Intrathecal SACT Assessment Questions Core General Questions must be completed by all staff. 1. Intrathecal must never be abbreviated to IT on a prescription form 2. Intrathecal SACT must be
More informationClinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327
Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More informationThe first and only treatment for spinal muscular atrophy (SMA)
Discover SPINRAZA The first and only treatment for spinal muscular atrophy (SMA) INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.
More informationGUIDELINES FOR PERFORMING AN INTRAPERITONEAL UROKINASE LOCK
GUIDELINES FOR PERFORMING AN INTRAPERITONEAL UROKINASE LOCK Contact Name and Job Title (author) Directorate & Speciality Jr Sr Vanessa Keill Diabetes, Infection, Renal and Cardiovascular Directorate (Renal
More informationDay care adenotonsillectomy in sleep apnoea
Day care adenotonsillectomy in sleep apnoea Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Day care adenotonsillectomy in presence of sleep apnoea 1a 2a 2b Contact
More informationSeasonal Influenza in Pregnancy and Puerperium Guideline (GL1086)
Seasonal Influenza in Pregnancy and Puerperium Guideline (GL1086) Approval Approval Group Job Title, Chair of Committee Date Maternity & Children s Services Clinical Governance Committee Chair, Maternity
More informationSpinraza (nusinersen)
Spinraza (nusinersen) Policy Number: 5.02.540 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Spinraza
More informationSPINRAZA READINESS KIT
SPINRAZA READINESS KIT Please see full Prescribing Information for Important Safety Information. MANAGEMENT OF THE REIMBURSEMENT PROCESS FOR SPINRAZA 1 SELECT TREATMENT AFTER DISCUSSING BENEFITS AND RISKS
More informationGuideline for surveillance for hip subluxation and dislocation in children and young people with cerebral palsy. Speciality: General
Title of Guideline Contact Name and Job Title (author) Directorate & Speciality Guideline for surveillance for hip subluxation and dislocation in children and young people with cerebral palsy Janet Corderoy,
More informationDOCUMENT CONTROL PAGE
DOCUMENT CONTROL PAGE Title Title: UNDERGOING SPINAL DEFORMITY SURGERY Version: 2 Reference Number: Supersedes Supersedes: all other versions Description of Amendment(s): Revision of analgesia requirements
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy
More informationGuidelines for the use of G-CSF in the Department of Oncology
Guidelines for the use of G-CSF in the Department of Oncology Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2018 10/2019 10/2018 Description of Procedure or Service Spinal muscular atrophy
More informationDOSAGE FORMS AND STRENGTHS Injection: 12 mg/5 ml (2.4 mg/ml) in a single-dose vial (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPINRAZA safely and effectively. See full prescribing information for SPINRAZA. SPINRAZA (nusinersen)
More informationChemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture
COMPANY: Biogen PRODUCT TRADE NAME: SPINRAZA GENERIC NAME: nusinersen INDICATION: SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Nusinersen Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 5 References... 5 Effective Date... 10/15/2017 Next
More informationGuideline for the Post Operative Management of Women who have received Intrathecal or Epidural Opioid Analgesia for Caesarean Section
Guideline for the Post Operative Management of Women who have received Intrathecal or Epidural Opioid Analgesia for Caesarean Section Speciality: Maternity Approval Body: Labour Ward Forum Approval Date:
More informationSPINRAZA (NUSINERSEN)
SPINRAZA (NUSINERSEN) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0059D Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationStaff at the Nottingham Children s Hospital. Guidelines process.
Diabetes and Surgery Title of Guideline Contact Name and Job Title (author) Guideline for the management of children and young people with diabetes aged 18 or under requiring surgery Dr Priyha Santhanam,
More informationYou ve found a treatment center. What might be next?
You ve found a treatment center. What might be next? The next step is to get acquainted with the process for receiving SPINRAZA by talking to the point of contact at the treatment center and the administering
More informationCEWT (Children s Epilepsy Workstream in Trent) Guidelines process.
ttingham Children s Hospital ttingham University Hospitals Seizure with Fever Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author)
More informationPrior Authorization Update: Nusinersen
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGUIDELINE FOR THE POST OPERATIVE MANAGEMENT OF WOMEN WHO HAVE RECEIVED INTRATHECAL OR EPIDURAL OPIOID ANALGESIA FOR CAESAREAN SECTION
GUIDELINE FOR THE POST OPERATIVE MANAGEMENT OF WOMEN WHO HAVE RECEIVED INTRATHECAL OR EPIDURAL OPIOID ANALGESIA FOR CAESAREAN SECTION Originator: Maternity Services & Anaesthetics Dept Date Approved: January
More informationAmy-Jo Hooley Specialist Clinical Pharmacist
Gut Decontamination Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the Safe Administration
More informationLRI Children s Hospital
LRI Children s Hospital Guideline for the Care of Neonates, Children and Young People Requiring Epidural Analgesia Staff relevant to: All Health Professionals who care for neonates, children and young
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY
CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that
More informationSUMMARY OF RELEVANT CODES FOR SPINRAZA
SUMMARY OF RELEVANT CODES FOR SPINRAZA Please see full Prescribing Information for additional Important Safety Information. SUMMARY OF RELEVANT CODES FOR SPINRAZA ICD-10-CM CODE EXAMPLES ICD-10-CM Code
More informationBurn Wound Assessment and Infections
Burn Wound Assessment and Infections Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Family Health:
More informationFinal Phase 3 Study Data Show SPINRAZA (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
MEDIA CONTACT: Biogen Ligia Del Bianco Ph: +1 781 464 3260 public.affairs@biogen.com INVESTOR CONTACT: Biogen Ben Strain Ph: +1 781 464 2442 IR@biogen.com Final Phase 3 Study Data Show SPINRAZA (nusinersen)
More informationIntrathecal. By the end of this chapter, you will be able to: Introduction. Chapter 20
Chapter 20 Intrathecal Preparations By the end of this chapter, you will be able to: l Describe the specific risks with intrathecal cytotoxic products l List five checks that need to be carried out on
More informationPOLICY FOR INTRATHECAL CYTOTOXIC CHEMOTHERAPY
Affiliated Teaching Hospital TPPP No: MedsMgt 9 POLICY FOR INTRATHECAL CYTOTOXIC CHEMOTHERAPY Version: 7 Date ratified: October 2016 Ratified by: (Name of Committee): Name of originator/author, job title
More informationconcentrate intravenous solution and other strong potassium solutions
Policy for the use of potassium chloride concentrate intravenous solution and other strong potassium solutions CLINICAL GUIDELINES ID TAG Policy for the use of potassium chloride Title: concentrate intravenous
More informationP01. Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) P01 Guideline for Peak flow recording
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for Peak flow recording Caroline Youle,
More informationSpinal Muscular Atrophy in 2017
Spinal Muscular Atrophy in 2017 Leigh Maria Ramos-Platt, MD Children s Hospital of Los Angeles University of Southern California Keck School of Medicine Disclosures MDA Care Center Grant In this presentation,
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (FINAL) Nusinersen (Spinraza Biogen Canada Inc.) Indication: Treatment of 5q Spinal Muscular Atrophy RECOMMENDATION: The CADTH
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No.7 Hib/MenC vaccination programme NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information
More informationvaccinators and criteria for pharmacist vaccinators
Appendix 4: Authorisation of vaccinators and criteria for pharmacist vaccinators Appendix 4: Authorisation of vaccinators and criteria A4.1 Protocol for authorisation of vaccinators and pharmacist vaccinators
More informationSUMMARY OF RELEVANT CODES FOR SPINRAZA
SUMMARY OF RELEVANT CODES FOR SPINRAZA Please see accompanying full Prescribing Information for additional Important Safety Information. SUMMARY OF RELEVANT CODES FOR SPINRAZA ICD-10-CM CODE EXAMPLES ICD-10-CM
More informationDiagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1
Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1 17 th April 2018 Adnan Manzur Consultant Paediatric Neurologist Dubowitz Neuromuscular Centre, GOSH & ICH,
More informationNusinersen Use in Spinal Muscular Atrophy
Nusinersen Use in Spinal Muscular Atrophy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Slide 1 Evidence in Focus Endorsement and
More informationSPINRAZA (nusinersen) CLINICAL OVERVIEW
SPINRAZA (nusinersen) CLINICAL OVERVIEW IN BOTH CONTROLLED AND OPEN-LABEL STUDIES, SOME PATIENTS WHO HAD OR WERE LIKELY TO DEVELOP SPINAL MUSCULAR ATROPHY (SMA) TYPE 1, 2, OR 3 TREATED WITH SPINRAZA 1
More informationNational Hospital for Neurology and Neurosurgery
National Hospital for Neurology and Neurosurgery Venous sinus stents (for the treatment of venous sinus stenosis and idiopathic intracranial hypertension) Lysholm Department of Neuroradiology If you would
More informationCardiac Catheter Labs Intravenous Drug Therapy Guide
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Cardiac Catheter Lab IV Medicines Guideline Helen Buxton ( Senior Cath Lab
More informationReducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway
Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Dr Alex Williams, Oncology Specialty Doctor. Cheltenham General Hospital Oncology Centre
More informationSaline (0.9%) Nebuliser Guideline
Saline (0.9%) Nebuliser Guideline Full Title of Guideline: Author (include email and role): Division & Speciality: Version: 3 Ratified by: Scope (Target audience, state if Trust wide): Review date (when
More informationRoche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics.
Media Release PRIME designation granted by European Medicines Agency for Roche s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the
More informationSTANDARDIZED PROCEDURE REPROGRAMMING AND REFILLING INTRATHECAL BACLOFEN PUMPS and ACCESSING THE CATHETER ACCESS PORT (Adult,Peds)
I. Definition The purpose of this procedure is to allow the Advanced Health Practitioner (AHP) to reprogram and refill intrathecal Baclofen pumps, as well as access the catheter access port for those AHPs
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationLumbar drains. Information for patients Neurosurgery
Lumbar drains Information for patients Neurosurgery Why do I need drainage of my cerebrospinal fluid (CSF)? The brain and spinal cord are bathed in clear fluid like a baby in the womb. This cerebrospinal
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No.4 Immunisation against diphtheria, tetanus, poliomyelitis, pertussis and Hib programme Classification: official NHS England INFORMATION
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Pre-filled Patient Controlled Analgesia (PCA) syringes
The Newcastle upon Tyne Hospitals NHS Foundation Trust Pre-filled Patient Controlled Analgesia (PCA) syringes Version.: 2.2 Effective From: 1 June 2016 Expiry Date: 1 June 2019 Date Ratified: 20 April
More informationNusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study
21 st International Congress of the World Muscle Society -8 October, 2016 Granada, Spain Nusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From
More informationSAFE HANDLING OF VACCINES
STANDARD OPERATING PROCEDURE SAFE HANDLING OF VACCINES Issue History Issue Version One Purpose of Issue/Description of Change Planned Review Date To ensure vaccines are stored in accordance with manufacturers
More informationThis guideline describes the care required for a patient receiving a red blood cell transfusion whilst undergoing extra corporeal therapies.
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guidelines for care of a patient receiving a red blood cell transfusion whilst undergoing extra corporeal therapies.
More informationGuideline for the Use of inhaled Nitric Oxide (NO) Catarina Silvestre Prof. Harish Vyas
Inhaled Nitric Oxide Title of Guideline Guideline for the Use of inhaled Nitric Oxide (NO) 1a 2a 2b Contact Name and Job Title (author) Directorate & Speciality Date of submission October 2015 Date when
More informationTreatment. Zinbryta (daclizumab)
Information for people living with multiple sclerosis Treatment What is Zinbryta and how does it work? How is Zinbryta administered? Before you take Zinbryta While you are taking Zinbryta What are the
More informationParavertebral policy. The Acute pain Management Dept, UCLH
UCLH PARAVERTEBRAL BLOCK (ADULTS) POLICY Paravertebral policy. The Acute pain Management Dept, UCLH DEFINITION A Paravertebral block is a method of providing effective analgesia using a local anaesthetic.
More informationHerceptin SC (Subcutaneous Trastuzumab)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Rate 1 Herceptin SC (trastuzumab) 600mg S/C 2 to 5 mins *PRECAUTION: In order to reduce the risk of medication errors it is recommended that all trastuzumab
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE. PATIENT MEDICATION INFORMATION SPINRAZA nusinersen injection
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION SPINRAZA nusinersen injection Read this carefully before you or your child start receiving SPINRAZA and before each
More informationCROSS HEALTH CARE BOUNDARIES MATERNITY CLINICAL GUIDELINE. One
CROSS HEALTH CARE BOUNDARIES MATERNITY CLINICAL GUIDELINE Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline on the Use of the Interpreting Services within
More informationCONFIRMED INFLUENZA ISOLATES IN NORTHERN IRELAND - NICE GUIDANCE ON USE OF ANTIVIRALS NOW APPLIES
From the Chief Medical Officer Dr Michael McBride HSS(MD) 34/2018 FOR ACTION Chief Executives, Public Health Agency/Health & Social Care Board/HSC Trusts/ NIAS GP Medical Advisers, Health & Social Care
More informationVirginia Beach Department of Emergency Medical Services. CAAS # Index # Administration VACCINATION POLICY
Virginia Beach Department of Emergency Medical Services CAAS # 106.01.01 Index # Administration VACCINATION POLICY PURPOSE: This policy is designed to provide guidance in operating a program for the administration
More informationNew Drug Evaluation: Nusinersen Injection, Intrathecal
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCATHETER ACCESS KIT. For use with Prometra Programmable Infusion Systems
CATHETER ACCESS KIT Caution: Federal (USA) Law restricts this device to sale by or on the order of a physician. Table of Contents Contents... 3 Description... 3 Indications... 3 Contraindications... 3
More informationWITHDRAWN. Treatment. Zinbryta (daclizumab)
Information for people living with multiple sclerosis What is Zinbryta and how does it work? How is Zinbryta administered? Before you take Zinbryta While you are taking Zinbryta What are the potential
More informationPALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE. Chief Pharmacist. Chief Pharmacist
REFERENCE NUMBER: PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE AREA: NAME OF RESPONSIBLE COMMITTEE / INDIVIDUAL NAME OF ORIGINATOR / AUTHOR Trust-wide Chief Pharmacist Chief Pharmacist DATE
More informationPatient Group Directions (PGDs)
Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical
More informationTitle of Guideline (must include the word Guideline (not. Guidelines. Contact Name and Job Title (author)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date on which guideline must be
More informationDRUG GUIDELINE. HYDRALAZINE (Intravenous severe hypertension in pregnancy)
DRUG GUIDELINE HYDRALAZINE (Intravenous severe hypertension SCOPE (Area): FOR USE IN: Labour Ward, HDU, Theatre and ED EXCLUSIONS: Paediatrics (seek Paediatrician advice) and other general wards. SCOPE
More informationANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS
ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS Version 4.0 Date ratified February 2009 Review date February 2011 Ratified by Authors Consultation Evidence
More informationGuidance for Influenza in Long-Term Care Facilities
Guidance for Influenza in Long-Term Care Facilities DSHS Region 2/3 Epidemiology Team January 2018 1. Introduction Every year, the flu affects people around the world, regardless of age. However, residents
More informationFAQ Document for Guidance on the Safe Use of Intrathecal Chemotherapy in the Treatment of Cancer
FAQ Document for Guidance on the Safe Use of Intrathecal Chemotherapy in the Treatment of Cancer Table of Contents Introduction... 1 Recommendation 31 FAQs... 2 Question 1.... 2 Answer... 2 Recommendation
More informationDispensing and administration of emergency opioid antagonist without a
68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies
More informationInterim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants With Spinal Muscular Atrophy
American Academy of Neurology 2017 69th Annual Meeting April 22 28, 2017 Boston, MA Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants With
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationSAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein
Patient Group Direction for the supply or administration of haemophilus influenzae type B and meningococcal conjugate vaccine to children requiring immunisation as part of the national childhood vaccination
More informationCase scenarios: Patient Group Directions
Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationHaemophilia Suspected Bleed
Haemophilia Suspected Bleed Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the management
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No.14 Shingles immunisation programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations
More informationCommunity Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group
More informationTemplate Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices
Name of Dental Practice : Objectives To ensure implementation of the regulations and guidance on safe and secure handling of midazolam and other controlled drugs (CDs) Scope To cover all aspects of obtaining
More informationIntrathecal chemotherapy
Intrathecal chemotherapy Chemotherapy A guide for patients and carers Contents What is intrathecal chemotherapy?... 1 Why do I need intrathecal chemotherapy?... 1 What will happen before the procedure?...
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationFinal Results of the Phase 3 ENDEAR Study Assessing the Efficacy and Safety of Nusinersen in Infants With Spinal Muscular Atrophy (SMA)
69th Annual Meeting of the American Academy of Neurology April 22-28, 2017 Boston, MA, USA Final Results of the Phase 3 ENDEAR Study Assessing the Efficacy and Safety of Nusinersen in Infants With Spinal
More informationTrust Guideline for the Management of Patient Controlled Analgesia (PCA) in Adults
Patient Controlled Analgesia (PCA) in Adults A clinical guideline recommended for use For Use in: In all Clinical Areas By: Anaesthetists, Ward Nurses, Recovery Staff Acute Pain Service Staff For: Adult
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More informationPanel II: SMA Drugs in Development
Panel II: SMA Drugs in Development Jinsy Andrews MD, Director of Clinical Research and Development, Cytokinetics Thomas Blaettler MD, Global Clinical Development Team Leader, F. Hoffmann-La Roche Jerry
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is
More informationClinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages)
Clinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages) Reference: NHS England: 16042/P NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More information